Calico Life Sciences LLC

Privately held: no public share price · United States

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2/3
EIF2B (eIF2B activator)
Indication not yet linked
Phase 1
PTPN2/PTPN1Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
FosigotifatorPhase 1/2Vanishing White Matter Disease
Est. primary completion 2027-11 · NCT05757141 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 January 2025Topline resultFosigotifatorHEALEY ALS Platform Trial Regimen F (NCT05740813) Phase 2/3 missed its primary endpoint
Calico Life Sciences LLC (Calico) · Source ↗

Financial reports

No financial reports recorded.